Ramucirumab in the treatment of non-small cell lung cancer

Arrieta, Óscar; Zatarain-Barrón, Zyanya Lucía; Cardona, Andrés Felipe; Carmona, Amir; Lopez-Mejia, Mariana

doi:10.1080/14740338.2017.1313226

Cited by 24 publications

(11 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other than reports regarding nivolumab, there have been few reports on thyroid or pituitary dysfunction associated with the anticancer agents that our patient took, including bevacizumab and ramucirumab (Fig. 3) [26–29]. External brain radiotherapy can produce pituitary dysfunction that is usually associated with GH deficiency, but it seldom causes IAD [30].…”

Section: Discussionmentioning

confidence: 95%

Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature

et al. 2019

View full text Add to dashboard Cite

IntroductionImmune checkpoint inhibitors are a promising class of anticancer drugs. The clinical benefits afforded by immune checkpoint inhibitors can be accompanied by immune-related adverse events that affect multiple organs, and endocrine immune-related adverse events include thyroiditis and hypophysitis. Hypophysitis is less frequent and has a less severe clinical presentation in patients treated with other immune checkpoint inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, than in those treated with ipilimumab. However, studies have described isolated adrenocorticotropic hormone deficiency cases associated with nivolumab, pembrolizumab, and atezolizumab therapy, most of which occurred during the course of immune checkpoint inhibitor therapy. We report a rare case of patient with isolated adrenocorticotropic hormone deficiency that occurred after nivolumab therapy.Case presentationA 69-year-old Japanese woman with advanced lung adenocarcinoma developed painless thyroiditis with transient elevations of serum thyroid hormones during 3 months of cancer treatment with nivolumab and began thyroid hormone replacement therapy for subsequent primary hypothyroidism. Four months after nivolumab therapy was discontinued, she developed isolated adrenocorticotropic hormone deficiency; corticosteroid replacement therapy relieved her secondary adrenal insufficiency symptoms, such as anorexia and fatigue. Human leukocyte antigen typing revealed the presence of DRB1*04:05-DQB1*04:01-DQA1*03:03 and DRB1*09:01-DQB1*03:03-DQA1*03:02 haplotypes, which increase susceptibility to autoimmune polyendocrine syndrome associated with thyroid and pituitary disorders in the Japanese population.ConclusionsOur patient developed thyroiditis during cancer treatment with nivolumab and subsequently exhibited isolated adrenocorticotropic hormone deficiency 4 months after discontinuing the drug. Administration of nivolumab in combination with a genetic predisposition to polyglandular autoimmunity probably caused both the thyroiditis and hypophysitis, resulting in primary hypothyroidism and isolated adrenocorticotropic hormone deficiency, respectively, in our patient. The present case highlights the need for physicians to be aware that endocrine immune-related adverse events, including hypophysitis, can occur more than several months after discontinuing a drug.

show abstract

Section: Discussionmentioning

confidence: 95%

Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Ramucirumab is a humanized monoclonal antibody that selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2) and blocks the interaction of VEGFR-2 with VEGF. Ramucirumab has been approved for application in colorectal cancer, non-small cell lung cancer and stomach adenocarcinoma or an gastroesophageal junction adenocarcinoma that has metastasized [57][58][59]. Clinical experiments have shown that the combination of ramucirumab and docetaxel prolonged PFS in patients with locally advanced or metastatic urothelial carcinoma, which further guarantees investigation in a phase III trial [60].…”

Section: Monoclonal Antibody Therapymentioning

confidence: 99%

The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

Yong

et al. 2019

Cells

View full text Add to dashboard Cite

Tumor vessels provide essential paths for tumor cells to escape from the primary tumor and form metastatic foci in distant organs. The vessel targeting strategy has been widely used as an important clinical cancer chemotherapeutic strategy for patients with metastatic tumors. Our review introduces the contribution of angiogenesis to tumor metastasis and summarizes the application of Food and Drug Administration (FDA)-approved vessel targeting drugs for metastatic tumors. We recommend the application and mechanisms of vascular targeting drugs for inhibiting tumor metastasis and discuss the risk and corresponding countermeasures after vessel targeting treatment.

show abstract

“…69 Ramucirumab is a specific inhibitor for VEGFR2. 70 It has been demonstrated that the application of Ramucirumab as second-line treatment drug did not significantly improve the survival rate of patients with advanced HCC. *The clinical trial data was obtained from ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home), searching for "liver cancer" or "hepatocellular carcinoma" as keywords, and clinical trials with a number of cases of not less than 25 and following the standard of the case-control design were listed.…”

Section: Vegf Fgf and Pdgf-targeted Therapy For Hccmentioning

confidence: 99%